Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-1830
- Development stage
- Preclinical
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Percutaneous
01
Overview
TNX-1830 is a live viral vector vaccine candidate based on a modified horsepox virus designed to express specific, non-Spike protein antigens from SARS-CoV-2 for the prevention of COVID-19. Unlike related candidates such as TNX-1800, which expresses the Spike protein, TNX-1830 is engineered to express different SARS-CoV-2 antigens to induce an immune response—primarily aiming for an almost pure T cell response—in an effort to provide protection against variants and to explore broader antigen targets. It is under development by Tonix Pharmaceuticals in collaboration with the University of Alberta[1][2][3][4][5].
Beyond the preview
Go deeper on TNX-1830.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-1830.